Drug intelligence / Profile preview

OWL-1023-AI

Development stage: Preclinical
Lead developer: Owl Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

OWL-1023-AI is a preclinical-stage monoclonal antibody being developed by Owl Therapeutics, a subsidiary of Gryphon Bio, for the treatment of Alzheimer's Disease (AD) and Traumatic Brain Injury (TBI). Engineered using a generative AI platform and biomarker-powered precision medicine approaches, the drug is designed to 'supercharge' microglia, the resident immune cells of the brain. Its primary mechanism of action involves enhancing microglial phagocytosis of brain cell debris and pathogens, thereby supporting brain clearance mechanisms and neuroprotection. Unlike traditional monoclonal antibodies that target specific protein aggregates like amyloid-beta, OWL-1023-AI is designed to protect and enhance microglial function through a platform-designed mechanism.

Beyond the preview

Go deeper on OWL-1023-AI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OWL-1023-AI.

Explore the full profile